Arvinas Highlights Growing Phase 1 Pipeline, Near-Term Catalysts at TD Cowen Healthcare Conference [Yahoo! Finance]
Arvinas, Inc. (ARVN)
Last arvinas, inc. earnings: 11/4 05:00 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
of the AR degrader ARV-027 , and says it has the capital to advance its PROTAC protein-degradation platform. The LRRK2 degrader ARV-102 showed dose-dependent CSF exposure and LRRK2 reduction in healthy volunteers, with a Parkinson's Phase 1 readout due at the upcoming ADPD conference and plans to move into PSP studies thereafter. In oncology, enrollment for the KRAS G12D degrader ARV-806 is complete with first clinical data expected in 2026, the BCL6 degrader ARV-393 has shown early responses with first-in-human data anticipated in H2, and the breast-cancer candidate vepdegestrant faces a June 5 PDUFA decision as Arvinas pursues a commercialization partner (discussing Pfizer). Interested in Arvinas, Inc.? Here are five stocks we like better. 3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023 Executives from Arvinas (NASDAQ:ARVN) outlined recent pipeline progress and upcoming catalysts at TD Cowen's 46th Annual Healthcare Conference, highlighting a growing set of
Show less
Read more
Impact Snapshot
Event Time:
ARVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARVN alerts
High impacting Arvinas, Inc. news events
Weekly update
A roundup of the hottest topics
ARVN
News
- Arvinas (ARVN) had its price target raised by Citigroup Inc. from $15.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Prostate Cancer Market Competitive Landscape Report 2026: Comprehensive Insights About 230+ Companies and 265+ Drugs by Product Type, Stage, and Route of Administration [Yahoo! Finance]Yahoo! Finance
- Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials [Yahoo! Finance]Yahoo! Finance
- Arvinas (ARVN) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ARVN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "sellMarketBeat
- Arvinas (ARVN) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $20.00 price target on the stock, up from $16.00.MarketBeat
ARVN
Earnings
- 2/24/26 - Miss
ARVN
Sec Filings
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- ARVN's page on the SEC website